CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.
Mario L Marques-PiubelliDo Hwan KimL Jeffrey MedeirosWei LuKhaja KhanLorena Isabel Gomez-BolanosSaxon RodriguezEdwin R ParraChi Young OkAkanksha AradhyaLuisa M SolisYago L NietoRaphael SteinerSairah AhmedFrancisco VegaPublished in: Histopathology (2023)
Chimeric antigen receptor (CAR) T-cells anti-CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of patients who relapsed after this therapy. This is the first study to show decreased CD30 expression in R/R CHL in patients (n = 5) who underwent CAR T-cell therapy in our institution between 2018 and 2022. Although conventional immunohistochemical assays showed decreased CD30 expression in neoplastic cells in all cases (8/8) the tyramide amplification assay and RNAScope in situ hybridisation detected CD30 expression at different levels in 100% (n = 8/8) and 75% (n = 3/4), respectively. Hence, our findings document that certain levels of CD30 expression are retained by the neoplastic cells. This is not only of biological interest but also diagnostically important, as detection of CD30 is an essential factor in establishing a diagnosis of CHL.
Keyphrases
- hodgkin lymphoma
- cell therapy
- poor prognosis
- acute lymphoblastic leukemia
- nk cells
- induced apoptosis
- end stage renal disease
- diffuse large b cell lymphoma
- cell cycle arrest
- mesenchymal stem cells
- acute myeloid leukemia
- chronic kidney disease
- stem cells
- cell proliferation
- binding protein
- long non coding rna
- machine learning
- peritoneal dialysis
- oxidative stress
- signaling pathway
- artificial intelligence
- high throughput
- ejection fraction
- bone marrow
- quantum dots
- patient reported outcomes
- nucleic acid
- big data